Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: alcaftadine

« Back to Dashboard

Alcaftadine is the generic ingredient in one branded drug marketed by Allergan and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for alcaftadine. Three suppliers are listed for this compound.

Summary for Generic Name: alcaftadine

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Drug Master File Entries: see list4
Suppliers: see list3

Clinical Trials for: alcaftadine

Ocular Allergy Treatment Practical Impact Trial
Status: Recruiting Condition: Allergic Conjunctivitis; Rhinoconjunctivitis

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
Status: Completed Condition: Conjunctivitis, Allergic

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
Status: Completed Condition: Conjunctivitis, Allergic

A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
Status: Active, not recruiting Condition: Allergic Conjunctivitis

A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft
Status: Recruiting Condition: Allergic Conjunctivitis

Safety and Efficacy Study of a Eye Drop for Eye Allergy
Status: Completed Condition: Allergic Conjunctivitis

Comparison of Tolerability Between Two Allergy Drops
Status: Enrolling by invitation Condition: Allergic Conjunctivitis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134Jul 28, 2010RXYes<disabled><disabled>
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134Jul 28, 2010RXYes8,664,215<disabled><disabled>
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134Jul 28, 2010RXYes5,468,743<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc